pharmaceutical

Primary packaging for solid and liquid drugs - as well as many other products - benefits from the latest addition to the Thermolast M series

Primary packaging for solid and liquid drugs, as well as many other products, will benefit from the latest addition to the Thermolast M series. But Kraiburg TPE is also keeping abreast with the times organizationally: the service package that comes with the product ensures customers are always perfectly prepared for...

Stéphane Baudry, Chairman and CEO of Walden

Walden (formerly EHDH) announced that it has completed the acquisition of Movianto, thereby becoming the European leader in transport and logistics services for the pharmaceutical sector. Stéphane Baudry, Chairman and CEO of Walden, is the majority shareholder of the new group. This acquisition is made on the basis of...

Beauty from the dropper bottle with pipette. This allows precious active ingredients to be dosed precisely

Many high-quality cosmetics and care products are offered in pharmacies. In addition, the trend of filling high-quality care products such as anti-aging cosmetics in pharmaceutical bottles continues unchanged. A dropper bottle with a pipette is ideal for the precious active ingredients, of which often only a few drops...

Asahi Glassplant UK acquires Syrris and Glass Solutions

Asahi Glassplant UK Ltd. announce the successful acquisition of the Syrris and Glass Solutions businesses from Blacktrace Holdings Ltd. (Blacktrace), Royston, UK, on 1st January 2020. Asahi Glassplant UK, a subsidiary of Asahi Glassplant Inc., Japan, is a world-leading innovator in glass technology for scientific...

The new company building

A new plant for producing plastic pharmaceutical packaging has been set up in the Chinese city of Changzhou to help satisfy the high demand for Gerresheimer’s primary packaging in China in the future. “From now on, we will also have production facilities in China to meet the needs of our customers and partners,” says...

Big pharma’s healthy outlook

Big pharma is facing down critics worried that expiring patents, a lack of new blockbuster treatments, constrained healthcare budgets and squeezed drug prices would up-end its business model. The success of orphan drugs is one reason why. Sales of treatments for rare diseases - known as orphan drugs - are growing fast...

H+E GmbH and Austar Group forges Joint Venture for pharma market

H+E has founded a new joint venture: H+E Pharma GmbH, located in Stuttgart - together with the well-established Austar Group in order to provide better and more efficient support for our customers. H+E Pharma’s business will concentrate on the development, engineering, production, and sales of systems and parts for...